Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main objective is to identify specific risk factors for ANCA vasculitis of occupational and/or environmental origin (exposures identified by questioning, geographical distribution of cases) from the RNV3P data.
The secondary objectives are as follows:
Description of cases of ANCA vasculitis seen in French occupational pathology consultation centres:
Identification of specific risk factors for ANCA vasculitis of occupational and/or environmental origin (exposures identified on questioning, geographical distribution of cases).
For occupational and non-occupational cases of ANCA vasculitis: identification of difficulties encountered by patients at work and proposed work adaptations.
Estimation of the number of applications for recognition of disabled worker status made within this patient group.
Identification of clinical severity and autoimmune profiles of ANCA vasculitis of occupational and/or environmental origin.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of diagnoses of ANCA vasculitis in the RNV3P | Number of diagnoses of ANCA vasculitis coded in the RNV3P or mentioned as the disease motivating the consultation in the summary by text mining search. | 4 months |
| Measure | Description | Time Frame |
|---|---|---|
| Imputability of the coded diagnoses of ANCA vasculitis. | Number of patients with ANCA vasculitis seen in consultation in occupational disease consultation centres for which a link between occupational and/or environmental exposure and the patient's ANCA vasculitis was retained. The imputability is coded in the RNV3P database by the clinician who saw the patient, for each exposure recorded in the database, according to the pathology selected and the patient's exposure following the completion of the patient's laboris and environmental curriculum. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with ANCA vasculitis seen in French occupational disease consultation centres.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Greta GOURIER | Contact | 0298223509 | greta.gourier@chu-brest.fr | |
| Brice LODDE | Contact | brice.lodde@chu-brest.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Bordeaux | Bordeaux | France |
|
All collected data that underlie results in a publication
Data will be available beginning 3 months and ending five years following the publication
Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.
Not provided
Not provided
Not provided
Not provided
Not provided
| 4 months |
| Number of patients with ANCA vasculitis for whom occupational and/or environmental exposure to microcrystalline silica was identified. | Number of patients with ANCA vasculitis seen in consultation in occupational disease consultation centres for whom occupational and/or environmental exposure to microcrystalline silica was identified. | 4 months |
| Number of patients with ANCA vasculitis for whom other occupational and/or environmental exposure was identified. | Number of patients with ANCA vasculitis seen in consultation in occupational disease consultation centres for whom other occupational and/or environmental exposure was identified. | 4 months |
| Number of patients with ANCA vasculitis for whom an application for recognition as a disabled worker has been submitted. | Number of patients with ANCA vasculitis seen in consultation in occupational disease consultation centres for whom an application for recognition as a disabled worker has been submitted. | 4 months |
| CHU de Grenoble | Grenoble | France |
|
| CHU de LILLE | Lille | France |
|
| HCL | Lyon | France |
|
| AP-HM | Marseille | France |
|
| CHU de Nancy | Nancy | France |
|
| CHU de Nantes | Nantes | France |
|
| Hôpital Cochin ( AP-HP) | Paris | France |
|
| CHU de Rennes | Rennes | France |
|
| CHU de Strasbourg | Strasbourg | France |
|
| CHU de Toulouse | Toulouse | France |
|
| ID | Term |
|---|---|
| D056648 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis |
| D009784 | Occupational Diseases |
| ID | Term |
|---|---|
| D056647 | Systemic Vasculitis |
| D014657 | Vasculitis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D017445 | Skin Diseases, Vascular |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided